Silverback Therapeutics

SPRY50

$11.36arrow_drop_down3.31%-$0.39

SPRY50

$11.36

arrow_drop_down3.31%-$0.39

Performance History

Key Stats
Open	$11.76
Prev. Close	$11.75
EPS	-0.47
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	11.00	11.76
52 Week Range	2.55	16.50

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.47

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Silverback Therapeutics (SPRY)

ARS Pharmaceuticals, Inc., also known as SPRY, is a pharmaceutical company that specializes in the development and commercialization of novel therapies for respiratory diseases. The company focuses on creating innovative treatments to address unmet medical needs and improve the quality of life for patients. SPRY has a strong track record in bringing new drugs to market and has a robust pipeline of potential therapies in various stages of development.

As of the most recent trading day, SPRY had a stock price of $X, with a market capitalization of $X. The stock has shown resilience over the past year, with a 52-week range of $X to $X. This indicates that SPRY has managed to navigate through market fluctuations and maintain a steady performance. The day's trading volume for SPRY was X, highlighting the interest and activity surrounding the stock.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
Headquarters: San Diego
Employees: 29
Exchange: NASDAQ

add Silverback Therapeutics to watchlist

Keep an eye on Silverback Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Silverback Therapeutics (SPRY)?

Silverback Therapeutics (SPRY) has a market capitalization of $1.1B. The average daily trading volume is 1M, indicating the stock's liquidity and investor engagement.

help

What is Silverback Therapeutics 's (SPRY) price per share?

The current price per share for Silverback Therapeutics (SPRY) is $11.36. The stock has seen a price change of -$0.39 recently, indicating a -3.32% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Silverback Therapeutics (SPRY)?

For Silverback Therapeutics (SPRY), the 52-week high is $16.5, which is 45.25% from the current price. The 52-week low is $2.55, the current price is 345.49% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Silverback Therapeutics (SPRY) a growth stock?

Silverback Therapeutics (SPRY) has shown an average price growth of 0.41% over the past three years. It has received a score of 75 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Silverback Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Silverback Therapeutics (SPRY) stock price performance year to date (YTD)?

As of the latest data, Silverback Therapeutics (SPRY) has a year-to-date price change of 103.58%. Over the past month, the stock has experienced a price change of 16.16%. Over the last three months, the change has been 28.8%. Over the past six months, the figure is 27.35%.

help

Is Silverback Therapeutics (SPRY) a profitable company?

Silverback Therapeutics (SPRY) has a net income of -$54.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -3.07K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$67.52M. Furthermore, the EBITDA is -$56.67M.

News

ARS PHARMACEUTICALS

WEDBUSH PACGROW HEALTHCARE CONFERENCE

INTRANASAL EPINEPHRINE

SEVERE ALLERGIC REACTIONS

ANAPHYLAXIS

8/7/2024

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

6/28/2024

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

HEALTH

LICENSING AGREEMENTS

4/30/2024

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand